Zerigo Health provides an FDA-cleared, connected light therapy solution that enables Americans living with psoriasis, vitiligo, and eczema to self-administer narrowband ultraviolet B (NB-UVB) phototherapy at home or on the go. The core product is a handheld device paired with a smartphone app; prescription dosing is controlled via secure cloud-based technology and patients are remotely monitored and given personal coaching and support. The system aligns with American Academy of Dermatology guideline-recommended NB-UVB phototherapy and is designed to keep physicians and patients connected with personalized data and insights. The company said it will use the newly raised funds to expand its business reach. Zerigo raised $43M in a Series B round led by 7wireVentures. John E. Schellhorn is President and CEO, and the company is based in San Diego, California. Clarify Medical develops the Clarify Home Light Therapy System, a connected phototherapy device that uses a patient’s smartphone app to manage targeted narrowband UVB treatments. The FDA‑cleared System controls dose, frequency, and duration while monitoring dosing, adherence, patient progress, and satisfaction via cloud connectivity. Treatments are prescribed by physicians but administered at home with clinical precision, enabling remote physician oversight. The company has established Medicare coverage and says the System is now available nationally in the U.S. Clarify intends to use recent financing to commercialize the product, improve market access, and build awareness within the medical dermatology community. The announcement highlights a U.S. patient population of about 30 million people with psoriasis, vitiligo, and eczema and roughly 5,400 medical dermatologists.

Total raised

$61M

Funding rounds

2

Latest round

Series B

Latest activity

Oct 2021